CDKN2A and Miyoshi myopathy: On the basis of the role of tumour suppressor gene/protein p16 in the cell-cycle signalling pathway, and in view of the prevalence of mutations found in MM, Frizelle S.P. et al. used a p16 peptide (84-103 aa), which exerts minimal CDK-inhibitory activity, to transduce mesothelioma cells to inhibit CDK4\6 and evaluated its therapeutic potential in mesothelioma.